Latest Inhaler Stories
Positive Results Based on New DSCG Formulation & eFlow Technology Delivery MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma's inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma. Results showed decreases in mean...
SAN DIEGO, May 19 /PRNewswire/ -- Data from two presentations highlighting the use of Perforomist(R) (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease (COPD) patients were featured today at the International Conference of the American Thoracic Society in San Diego. In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue...
Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The changes will result in Schering-Plough assuming...
NAPA, Calif., May 14 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announced today that data from two presentations highlighting the use of Perforomist(R) (formoterol fumarate) Inhalation Solution will be featured in poster format at the International Conference of the American Thoracic Society on May 19, 2009 in San Diego. In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea...
NORTH WALES, Pa., May 5 /PRNewswire/ -- In support of World Asthma Day, May 5, 2009, Teva Respiratory has extended its partnership with Direct Relief International, a nonprofit humanitarian medical relief organization, to donate thousands of units of QVAR(R) (Beclomethasone HFA), an Inhaled Corticosteroid (ICS) to its Charitable Medicine Access Program. Direct Relief will distribute the medication to economically disadvantaged and uninsured patients through the National Association of...
Very few athletic trainers associated with National Collegiate Athletic Association (NCAA) programs said that they were following best practice standards for managing asthma among their athletes, according to a new study.For athletes with asthma, the dangers of the condition can be as mild as impacting athletic performance or so severe to be incapacitating, or deadly. The lead report is published in the American College of Sports Medicine's journal, Medicine & Science in Sports &...
LOURES, Portugal, April 15 /PRNewswire/ -- Hovione is pleased to announce that its licensee Daiichi Sankyo (Tokyo, Japan) has informed that it intends to use Hovione's TwinCaps(R) dry powder inhaler device in the launch of the compound CS-8958, an inhaled long-acting neuraminidase inhibitor active against the influenza virus. Daiichi Sankyo has completed patient enrolment for Phase III clinical trials in Japan and other Asian countries and results are expected to be released mid year,...
MIDLOTHIAN, Va., March 30 /PRNewswire/ -- PARI Respiratory Equipment's LC Sprint reusable nebulizer and TREK S portable compressor were both used in the filming of the final episode of "ER" that will air Thursday at 9pm on NBC. Numerous stars are reprising roles for the final season of "ER," including George Clooney and Julianna Margulies, so the return of PARI products goes hand in hand - as PARI nebulizers have been used on the show to highlight treatments for a variety of respiratory...
NEW YORK, March 6 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced after consultation with the U.S. Food and Drug Administration (FDA), that additional clinical studies of aclidinium bromide for the treatment of chronic obstructive pulmonary disease (COPD) will be conducted to provide further support for the selected regimens, including higher and/or more frequent doses. This decision follows a meeting with the FDA to review...
SYMBICORT provides a new, fast-acting(1) combination treatment option for millions of Americans with debilitating lung disease WILMINGTON, Del., Feb. 27 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic...
